Alpine Immune Sciences (NASDAQ:ALPN) Downgraded by Zacks Investment Research
According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “
ALPN has been the subject of a number of other research reports. ValuEngine downgraded shares of Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd. Oppenheimer set a $13.00 target price on shares of Alpine Immune Sciences and gave the company a buy rating in a research report on Tuesday, March 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $11.15.
Alpine Immune Sciences (NASDAQ:ALPN) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.01). As a group, analysts predict that Alpine Immune Sciences will post -2.67 earnings per share for the current fiscal year.
In other Alpine Immune Sciences news, VP James Paul Rickey bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was acquired at an average price of $4.95 per share, with a total value of $49,500.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 75.10% of the stock is currently owned by company insiders.
An institutional investor recently bought a new position in Alpine Immune Sciences stock. Leonard Rickey Investment Advisors P.L.L.C. acquired a new stake in Alpine Immune Sciences Inc (NASDAQ:ALPN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $42,000. Leonard Rickey Investment Advisors P.L.L.C. owned 0.05% of Alpine Immune Sciences at the end of the most recent reporting period. Institutional investors and hedge funds own 47.04% of the company’s stock.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
Featured Article: SEC Filing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.